Psychiatric Telehealth Prescribing 2026: DEA Extension and What It Means for Your Billing Operations

The DEA’s latest extension of its Ryan Haight Act telehealth prescribing exemptions — now running through December 31, 2026 — keeps the door open for controlled substance prescribing via telehealth without a prior in-person visit. That is genuinely good news for patients and for the psychiatric practices that rebuilt their service models around telehealth access during and after the public health emergency. What we are seeing at roughly 50 behavioral health practices we work with, however, is that the clinical team understands this extension far better than the billing team does. That gap is costing practices real money.

The billing consequences of telehealth prescribing are not abstract. Wrong place-of-service codes, missing audio-video modifiers, and mismatched diagnosis-to-service pairings are generating denials at rates we are tracking between 18% and 31% on telehealth psychiatric medication management claims specifically. This post is our operational breakdown of what the 2026 extension actually requires at the claim level, and what you should be auditing right now.

What the 2026 DEA Extension Actually Changes (and Does Not Change)

The DEA’s third extension of the COVID-era telehealth prescribing flexibilities, published in late 2024 and effective through the end of 2026, continues to permit practitioners to prescribe Schedule III-V controlled substances via audio-visual telehealth without a prior in-person evaluation, provided several conditions are met. Schedule II substances — including stimulants for ADHD and certain medications used in pain management — remain subject to tighter constraints under the DEA’s proposed special registration framework, which has not yet been finalized as of early 2026.

From a billing standpoint, the extension does not modify payer-specific requirements. CMS rules under the Consolidated Appropriations Act of 2023 already extended Medicare telehealth flexibilities through 2026 as well, which means the two frameworks are temporarily aligned. But commercial and Medicaid payers have their own telehealth prescribing policies layered on top of federal rules. A blanket assumption that “DEA extended it, so we’re covered everywhere” is one of the most expensive mistakes we see practices make.

CPT Codes and Modifiers That Actually Matter for Psychiatric Telehealth Prescribing

Psychiatric medication management via telehealth runs through a specific and well-defined code set. The codes your billing team should be working with for 2026 include:

• 90833: Psychiatric diagnostic evaluation add-on when performed with E&M — used when a prescriber is conducting both evaluation and medication management in a telehealth visit
• 90836: Psychotherapy add-on with E&M, 30 minutes — relevant when a prescribing psychiatrist is also delivering brief psychotherapy
• 99213 and 99214: The E&M codes that anchor most psychiatric medication management visits; 99214 (moderate complexity) is appropriate for most established-patient controlled substance telehealth visits and reimburses at approximately $115-$148 under 2026 Medicare fee schedules depending on geographic adjustment
• 99205: New patient, high complexity — appropriate for initial telehealth psychiatric evaluations involving complex medication histories; reimbursed at approximately $220-$267 under Medicare 2026 rates

The modifier picture is where we see the most billing errors. For Medicare, Place of Service (POS) 10 (patient home/telehealth) is required for services delivered to a patient at home. The 95 modifier (synchronous audio-video telehealth) is required by most commercial payers. Using POS 02 instead of POS 10 on a home-based telehealth claim results in a reimbursement reduction of approximately 6.89% under the Medicare 2026 fee schedule — and in some cases triggers an outright denial from commercial payers who require POS 10 for remote prescribing encounters. Across a mid-size psychiatric practice seeing 1,200 telehealth visits per month, that modifier error alone represents $8,000-$14,000 in monthly revenue loss.

Schedule II Prescribing: The Grey Zone That DEA Has Not Resolved

We want to be direct here because this is the area where the 2026 extension creates the most operational ambiguity. The extension does not resolve Schedule II prescribing. For ADHD-focused psychiatric practices or practices that prescribe stimulants as part of a broader behavioral health service line, the question of whether a patient can receive a Schedule II prescription via telehealth without a prior in-person visit is still governed by the DEA’s proposed special registration rule, which had not been finalized as of Q1 2026.

Until that rule is finalized, practices prescribing Schedule II substances to telehealth-only patients are operating under a temporary exercise of prosecutorial discretion by the DEA — not a clear legal exemption. That distinction matters to your compliance officer and to any payer conducting a telehealth prescribing audit. We recommend documenting every Schedule II telehealth prescribing encounter with explicit notation of the clinical necessity, the patient’s treatment history, and the prescribing clinician’s assessment of why telehealth was appropriate. That documentation is your first line of defense in a payer audit and in any DEA inquiry.

Payer Policy Divergence: Where Commercial Denials Are Actually Coming From

The pattern we are seeing at the practices in our network is that Medicare and Medicaid telehealth prescribing claims are clearing at higher rates than commercial claims in 2026. The reason is that commercial payers have been slower to update their telehealth prescribing policies to match the federal extension, and several major carriers still impose prior-in-person-visit requirements for controlled substance prescribing that go beyond what federal law now requires.

United Healthcare, Cigna, and several regional Blues plans have telehealth prescribing riders in their provider contracts that are worth auditing specifically. If your practice is seeing denial rates above 15% on telehealth psychiatric E&M claims, the payer policy layer is almost certainly part of the problem. This is also where MHPAEA parity obligations become operationally relevant: if a payer is imposing a telehealth prescribing restriction on psychiatric medication management that it does not impose on equivalent medical specialty services, that restriction may be a parity violation worth appealing. Our team has written in detail about how behavioral health practices are leaving money on the table by not pursuing MHPAEA parity appeals, and telehealth prescribing denials are one of the clearest current examples.

SUD Prescribing: Buprenorphine Telehealth Billing in 2026

One dimension of the DEA extension that SUD practices need to track separately is buprenorphine prescribing. The SUPPORT Act and subsequent DEA guidance removed the DATA waiver (X-waiver) requirement for buprenorphine prescribing in 2023, and that change remains in effect. The 2026 DEA extension applies to buprenorphine as a Schedule III substance, which means qualifying practitioners can continue prescribing it via telehealth without a prior in-person visit through the end of 2026.

For SUD practices, the billing implication is that buprenorphine induction and medication management visits delivered via telehealth should be coded with the same CPT and modifier framework described above (99213/99214 with POS 10 and modifier 95 for most commercial payers), with HCPCS code H0020 or T1012 potentially applicable depending on the payer and program type. SUD practices that are also performing drug screening in conjunction with telehealth prescribing visits should be reviewing their screening code utilization carefully — we see significant undercoding on drug screens that represent 4-5x the revenue per test that practices are currently capturing, which we cover in detail in our post on G0480-G0483 drug screen coding for SUD practices.

What to Audit Before the 2026 Extension Expires

The December 31, 2026 deadline is a hard stop unless Congress or the DEA acts again. Practices that wait until Q4 2026 to audit their telehealth prescribing workflows will not have enough time to correct billing patterns, renegotiate payer contracts, or establish compliant in-person visit protocols for patients who will need them after the extension expires. The audit work we recommend starting now includes:

• A 90-day look-back on all telehealth psychiatric claims denied for prescribing-related reasons, sorted by payer and by rendering provider
• Verification that POS 10 is being applied correctly for all home-based telehealth visits and POS 02 for facility-based telehealth, with no mixed usage
• Modifier 95 and GT modifier mapping confirmed against current payer-specific requirements — these are not interchangeable across all payers in 2026
• Documentation audit for Schedule II prescribing encounters specifically, given the unresolved regulatory status
• Payer-by-payer telehealth prescribing policy review for your top five commercial payers by claims volume

If your denial rate on telehealth psychiatric medication management claims is above 12%, there is recoverable revenue in your existing claims history. At a practice billing 800 telehealth psychiatric visits per month at an average reimbursement of $130 per visit, a 20% denial rate represents roughly $24,960 in monthly revenue at risk — and a significant portion of that is recoupable through corrected claim resubmission and targeted appeals.

Take the Next Step: Free 30-Day Denial Audit

The 2026 DEA extension buys time, but it does not fix the billing and compliance gaps that are already generating denials in your telehealth prescribing claims. At Revenant Care Group, we work exclusively with behavioral health, ABA, and SUD practices, and our team has the payer-specific telehealth billing knowledge to identify exactly where your revenue is leaking. If you want a clear picture of what you are losing and what is recoverable, schedule your free 30-day denial audit here. No obligation, no generic report — just a practice-specific analysis of your telehealth claim performance with actionable findings your billing team can use immediately.